384 related articles for article (PubMed ID: 23558043)
1. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris.
Villano A; Di Franco A; Nerla R; Sestito A; Tarzia P; Lamendola P; Di Monaco A; Sarullo FM; Lanza GA; Crea F
Am J Cardiol; 2013 Jul; 112(1):8-13. PubMed ID: 23558043
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
Rousseau MF; Pouleur H; Cocco G; Wolff AA
Am J Cardiol; 2005 Feb; 95(3):311-6. PubMed ID: 15670536
[TBL] [Abstract][Full Text] [Related]
3. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
Chaitman BR; Skettino SL; Parker JO; Hanley P; Meluzin J; Kuch J; Pepine CJ; Wang W; Nelson JJ; Hebert DA; Wolff AA;
J Am Coll Cardiol; 2004 Apr; 43(8):1375-82. PubMed ID: 15093870
[TBL] [Abstract][Full Text] [Related]
4. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem.
Cocco G; Rousseau MF; Bouvy T; Cheron P; Williams G; Detry JM; Pouleur H
J Cardiovasc Pharmacol; 1992 Jul; 20(1):131-8. PubMed ID: 1383622
[TBL] [Abstract][Full Text] [Related]
5. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Stone PH; Gratsiansky NA; Blokhin A; Huang IZ; Meng L;
J Am Coll Cardiol; 2006 Aug; 48(3):566-75. PubMed ID: 16875985
[TBL] [Abstract][Full Text] [Related]
6. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
Thadani U; Ezekowitz M; Fenney L; Chiang YK
Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
[TBL] [Abstract][Full Text] [Related]
7. Ranolazine for the management of coronary artery disease.
Cheng JW
Clin Ther; 2006 Dec; 28(12):1996-2007. PubMed ID: 17296457
[TBL] [Abstract][Full Text] [Related]
8. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials.
Wenger NK; Chaitman B; Vetrovec GW
Am J Cardiol; 2007 Jan; 99(1):11-8. PubMed ID: 17196454
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
[TBL] [Abstract][Full Text] [Related]
10. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
Melloni C; Newby LK
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
[TBL] [Abstract][Full Text] [Related]
11. Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease.
Chaitman BR; Sano J
Clin Cardiol; 2007 Feb; 30(2 Suppl 1):I25-30. PubMed ID: 18373327
[TBL] [Abstract][Full Text] [Related]
12. Correlation between coronary microvascular function and angina status in patients with stable microvascular angina.
Di Franco A; Villano A; Di Monaco A; Lamendola P; Russo G; Stazi A; Scavone G; Nerla R; Sestito A; Lanza GA; Crea F
Eur Rev Med Pharmacol Sci; 2014; 18(3):374-9. PubMed ID: 24563437
[TBL] [Abstract][Full Text] [Related]
13. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial.
Arnold SV; Morrow DA; Wang K; Lei Y; Mahoney EM; Scirica BM; Braunwald E; Cohen DJ;
Circ Cardiovasc Qual Outcomes; 2008 Nov; 1(2):107-15. PubMed ID: 20031797
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
Chaitman BR
J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with ranolazine in a veteran population with chronic stable angina.
Reeder DN; Gillette MA; Franck AJ; Frohnapple DJ
Ann Pharmacother; 2012 Jan; 46(1):42-50. PubMed ID: 22215689
[TBL] [Abstract][Full Text] [Related]
16. [New agents for the therapy of angina pectoris].
Meinertz T; Köster R
Internist (Berl); 2011 Jul; 52(7):894-6, 898-900. PubMed ID: 21713611
[TBL] [Abstract][Full Text] [Related]
17. [Ranolazine--new treatment of chronic stable angina pectoris].
Ahlehoff O; Hansen PR
Ugeskr Laeger; 2009 Dec; 171(50):3705-7. PubMed ID: 20003868
[TBL] [Abstract][Full Text] [Related]
18. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials.
Zhu H; Xu X; Fang X; Zheng J; Zhao Q; Chen T; Huang J
Clin Ther; 2019 Oct; 41(10):2137-2152.e12. PubMed ID: 31548105
[TBL] [Abstract][Full Text] [Related]
19. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
Ling H; Packard KA; Burns TL; Hilleman DE
Am J Cardiovasc Drugs; 2013 Dec; 13(6):407-12. PubMed ID: 23873327
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.
Bairey Merz CN; Handberg EM; Shufelt CL; Mehta PK; Minissian MB; Wei J; Thomson LE; Berman DS; Shaw LJ; Petersen JW; Brown GH; Anderson RD; Shuster JJ; Cook-Wiens G; Rogatko A; Pepine CJ
Eur Heart J; 2016 May; 37(19):1504-13. PubMed ID: 26614823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]